Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd C.PHRM

Alternate Symbol(s):  PHRRF

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

GlobeNewswire November 24, 2021

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

GlobeNewswire November 11, 2021

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

GlobeNewswire November 3, 2021

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch

GlobeNewswire November 3, 2021

PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics

GlobeNewswire November 1, 2021

PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022

GlobeNewswire October 27, 2021

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor

GlobeNewswire October 27, 2021

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

GlobeNewswire October 19, 2021

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

GlobeNewswire October 13, 2021

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson's Disease

GlobeNewswire October 6, 2021

PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor

GlobeNewswire September 29, 2021

PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors

GlobeNewswire September 28, 2021

PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors

GlobeNewswire September 24, 2021

PharmaTher (CSE:PHRM) added to the North American Psychedelics Index & the Horizons Psychedelic Stock Index ETF

John Ballem  September 21, 2021

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

GlobeNewswire September 21, 2021

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

GlobeNewswire September 13, 2021

PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 9, 2021

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

GlobeNewswire September 7, 2021

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

GlobeNewswire August 10, 2021

PharmaTher (CSE:PHRM) granted FDA orphan drug designation for ketamine to treat ALS

John Ballem  August 4, 2021